Ulipristal acetate for the management of acute heavy menstrual bleeding without fibroids.

Abstract

Heavy menstrual bleeding is a common condition among women of childbearing age. Although hysterectomy was the usual approach in acute cases in the past, other minimally invasive therapies or pharmacological alternatives, such as the levonorgestrel intrauterine device have shown to be highly effective. This case report presents the case of a pluripathological patient with acute heavy menstrual bleeding and severe anemia, who was successfully managed with ulipristal acetate, a selective progesterone receptor modulator. Bleeding control was achieved in 6 d without side effects, avoiding the need for surgery. This report suggests that ulipristal acetate could be useful in the treatment of acute uterine bleeding even in a structurally normal uterus without fibroids.

• Authors: Josep Estadella, Pia Español, Fiorella Ascencio, Josep Perelló, Joaquim Calaf
• Journal: Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology (Gynecol Endocrinol) Vol. 34 Issue 7 Pg. 554-557 (Jul 2018) ISSN: 1473-0766 [Electronic] England
• PMID: 29260904 (Publication Type: Case Reports, Journal Article)

Chemical References

• Norpregnadienes
• ulipristal acetate

Topics

• Acute Disease
• Adult
• Female
• Humans
• Menorrhagia (drug therapy)
• Norpregnadienes (therapeutic use)
• Treatment Outcome
• Uterine Hemorrhage (drug therapy)